ABOS

ACUMEN PHARMACEUTICALS INC

ABOS·00509G209·US·Common Stock·Healthcare - Biotechnology-Activist

ABOS (ACUMEN PHARMACEUTICALS INC) is held by 65 institutional investors as of Q2 2026. Largest holders: RA CAPITAL MANAGEMENT, L.P. ($56.1M), BlackRock, Inc. ($6.6M), Alyeska Investment Group, L.P. ($6.6M). Net institutional sentiment: Mixed.

65
Holders
(4 Elite)
$101.6M
Total Value
65% (62)
Consensus
40 buying - 22 selling
13F: Insider & Congress: Updated regularly
ABOS

Smart Money Verdict

View all
Loading verdict
Held by 65 funds
4 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Mar 10, 2026 · Activists Apr 7, 2026 · Congress none

ActivistJBJames B. Murray Jr.5.0%Apr 7, 2026
ActivistRA Capital Management, L.P.RA Capital Management, L.P.29.5%Mar 17, 2026
InsiderMMMeisner Derek MSell $7KMar 6, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Unchanged
21M$56.1M0.5%-67.15%
0
Increased
2.5M(+1296.4%)$6.6M0.0%+11.89%
44
Unchanged
2.5M$6.6M0.0%-19.07%
0
Unchanged
2.3M$6.2M0.0%-27.34%
0
Increased
1.7M(+11.0%)$4.5M0.0%-10.06%
30
Increased
1.1M(+174.3%)$3M0.0%-4.76%
43
Decreased
955,000(-1.4%)$2.5M0.0%-13.56%
0
Unchanged
859,110$2.3M0.0%+19.11%
0
Increased
675,025(+42.4%)$1.8M0.0%+29.36%
35
Increased
622,882(+17.4%)$1.7M0.0%-9.81%
30
Increased
600,528(+295.8%)$1.6M0.0%+7.37%
28
Increased
360,744(+379.6%)$963,1870.0%+6.47%
40
New
320,795$856,5230.0%+9.36%
38
Increased
291,559(+143.5%)$778,9690.0%+1.47%
40
Increased
291,240(+46.2%)$777,6110.0%-6.04%
34
Decreased
274,781(-14.2%)$733,6650.0%+38.47%
0
New
189,712$506,5310.0%+9.36%
33
Decreased
183,927(-11.0%)$491,0850.0%+28.53%
0
Decreased
136,763(-5.4%)$365,1570.0%+24.93%
0
Decreased
126,104(-79.0%)$336,6980.0%+16.24%
0

Showing 1-20 of 75

1 / 4
ABOSABOSACUMEN PHARMACEUTICALS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used